Abstract: 5-Lipoxygenase-activating protein (FLAP) is an 18-kDa integral membrane protein required, in peripheral cells, for the activation of 5-lipoxygenase (5-LO) and for the resulting synthesis of leukotrienes from arachidonic acid. In the brain, the leukotrienes have been implicated in several pathophysiological events and in the electrophysiological effect of somatostatin, yet the cellular origin and role of these messenger molecules are still poorly understood. In the present study, we used reverse transcriptase-polymerase chain reaction, in situ hybridization, and immunohistochemistry to demonstrate that 5-LO and FLAP are expressed in various regions of the rat brain, including hippocampus, cerebellum, primary 01-factory cortex, superficial neocortex, thalamus, hypothalamus, and brainstem. Highest levels of expression were observed in cerebellum and hippocampus. In the latter we demonstrate the colocalization of 5-La and FLAP in CAl pyramidal neurons. Moreover, electrophysiological experiments show that selective inhibition of FLAP with the compound MK-886 (0.25-1 1sM) prevents the somatostatin-induced augmentation of the hippocampal KM -current. Our results provide necessary evidence for the presence and signaling role of 5-LO and FLAP in central neurons and strongly support their proposed participation in somatostatin-receptor transmembrane signaling.
pie cofactors to become fully active, including Ca 2ã nd ATP (Ford-Hutchinson et ai., 1994) . Rises in intracellular Ca2~cause the transiocation of 5-LO from cytosoi to membrane, where the enzyme interacts with an 18-kDa integral membrane protein, 5-lipoxygenase-activating protein (FLAP), required for leukotriene biosynthesis in peripheral cells Miller et al., 1990; Abramovitz et al., 1993) .
Arachidonic acid metabolism via the 5-LO pathway may play important roles in the CNS (for review, see Piomelli, 1994) . In vitro, preparations of brain tissue convert exogenous and endogenous arachidonic acid to leukotrienes and to other 5-LO products (Lindgren et al., 1984; Adesuyi et al., 1985; Shimizu et al., 1987) . In vivo, leukotriene biosynthesis is stimulated by the intracerebroventricular administration of platelet-activating factor and is associated with the induction of seizure activity, ischemia, and intracranial tumors (Simmet and Peskar, 1990; Hynes et al., 1991) . Moreover, LTC 4 exerts multiple actions on neural cells, such as prolonged excitation of cerebellar Purkinje neurons (Palmer et al., 1981) , stimulation of luteinizing hormone release from anterior pituitary cells (Kiesel et al., 1991) , and enhancement of the M-current (IM) in the hippocampal CAl field (Schweitzer et al., 1990 (Schweitzer et al., , 1993 .
The 'M is a noninactivating time-and voltage-dependent K~current (Brown and Adams, 1980) 
that, in
The leukotrienes, a family of biologically active metabolites of arachidonic acid, are synthesized through a sequence of enzymatic reactions initiated by 5-lipoxygenase (5-LO), a cytosolic dioxygenase that catalyzes both the initial oxidation of arachidonic acid to 5-hydroperoxy-6,8,1 1,14-eicosatetraenoic acid and its subsequent dehydration to leukotriene A4 (LTA4). LTA4 is short lived and may be rapidly transformed either into LTC4, by LTC4-synthase, or into LTB4, by LTA4-hydrolase (Samuelsson et al., 1987) . Unlike other mammalian lipoxygenases, 5-LO requires multi-hippocampal pyramidal neurons, is reduced by muscarinic receptor agonists (Halliwell and Adams, 1982) and augmented by the neuropeptide somatostatin (Moore et al., 1988) . Pharmacological evidence indicates that a 5-LO metabolite of arachidonic acid mediates the effect of somatostatin; 'M enhancement by somatostatin is prevented by drugs that inhibit phospholipase A 2 (PLA2) or 5-LO activities and mimicked by applications of exogenous arachidonic acid or LTC4 but not by application of LTB4 (Schweitzer et al., 1990 (Schweitzer et al., , 1993 .
Although these studies suggest a signaling role for We used the cDNAs obtained as templates to amplify, by PCR, DNA fragments corresponding to nucleotides -9 to 459 of rat FLAP sequence and nucleotides 442-1,028 of rat 5-LO sequence (Balcarek et al., 1988) . PCR conditions were as follows: 92°C, 56°C, and 72°C for I mm each; amplification of FLAP eDNA was performed for 15 cycles and that of 5-LO eDNA for 20 cycles. We subjected the PCR products to agarose (1%) gel electrophoresis and transferred them onto nitrocellulose. Prehybridization was at 56°C for 2 h in lOx Denhardt's solution/20 mM Na2HPO4/NaH2PO4 buffer, pH 6.8/5x standard saline citrate (SSC)/l% sodium dodecyl sulfate (SDS)/denaturated salmon sperm DNA (0.1 mg/ml). We performed hybridization for 3 h at 56°C, in prehybridization solution containing 10% dextran sulfate and 32P-labeled 46-mer oligonucleotide probes (5 X I~6 dpmlml) corresponding to nucleotides 86-132 (FLAP-I) and 285-331 (FLAP-2) of rat FLAP sequence and nucleotides 818-864 of rat 5-LO sequence (Balcarek et al., 1988) . We washed blots twice with 2X SSC/0.l% SDS/l0>< Denhardt's solution/lU mM Na 2HPO4/NaH,P04 buffer, pH 6.8, at 56°Cfor 30 mm.
In situ hybridization
We prepared and incubated brain sections essentially as described previously (Bouthenet et al., 1991) . For FLAP, hybridizations were performed in the presence of 50% formamide and 10 mM dithiothreitol, using synthetic 35S-labeled antisense oligonucleotides (base 89-109 for 5-LO and -6 to 14 for FLAP). We used as control a missense oligonucleotide (5 '-ACA TAT CTG ACT TCG AAT GCC-3'). In some experiments, distribution of 5-LO mRNA was confirmed by using a riboprobe prepared with a Promega riboprobe kit from a Smal-BamHI DNA fragment corresponding to nucleotides 1,417-1,735 of human 5-LO sequence (Dixon et al., 1988) , obtained by excision of a recombinant 5-LO pUC 13 plasmid vector (generously provided by Dr.
A. Ford-Hutchinson, Merck-Frosst, Canada) and subeloned in pGEM-4Z. We confirmed distribution of FLAP mRNA by using two 32P-labeled oligonucleotide probes, corresponding to nucleotides 86-132 and 285-331 of the rat FLAP sequence ).
Immunohistochemistry
After a 5-mm fixation with 4% paraformaldehyde, sections were rinsed in phosphate-buffered saline solution, incubated for 12 h at 4°Cwith FLAP antiserum (a gift of Dr.
A. Ford-Hutchinson) at a 1:500 dilution, rinsed, incubated with biotin-labeled anti-rabbit protein antiserum, treated with avidin/biotin/horseradish peroxidase complex and developed with diaminobenzidine for 5 mm.
Electrophysiology
We performed intracellular recordings in rat hippocampal slices, as described previously (Schweitzer et al., 1993 
RESULTS
We localized 5-La mRNA in rat CNS by in situ hybridization, using a 35S-labeled oligonucleotide probe. We found the highest labeling densities in hippocampus and cerebellum and moderate labeling in primary olfactory cortex, superficial neocortex, thalamus, hypothalamus, and brainstem (Fig. lA) . In situ hybridization with a 35S-labeled FLAP probe revealed a distribution of transcripts that appeared to overlap with that of 5-L0, with highest hybridization signals in hippocampus and cerebellum. In addition, clear signals were visible in primary olfactory cortex, neocortex, brainstem, and thalamus (Fig. 1B) . By contrast, only I. Neurochem., Vol. 66, No. I, /996 diffuse, nonspecific labeling was seen in adjacent sections treated with a control, 35S-labeled missense probe (Fig. 1C) . We obtained equivalent results using a labeled 5-LO riboprobe (derived from human 5-LO eDNA, which displays 93% identity with its rat homologue) and two additional 35S-labeled FLAP probes (data not shown).
RT-PCR analysis confirmed that 5-LO and FLAP mRNAs are expressed in rat brain. Southern blot analysis revealed PCR products of expected size when poly (A) + RNA samples from various regions of the rat brain were subjected to RT-PCR using oligonucleotide primers selective for 5-LO or FLAP (Fig. 2) . It is important that, although 5-LO and FLAP appear to be present throughout the brain, our RT-PCR conditions would not provide a quantitative assessment of their level of expression; i.e., more stringent quantitative PCR analyses must be performed to determine these levels.
To localize FLAP protein, we used a rabbit polyclonal antiserum selective for FLAP . We assessed the selectivity of the immunostaining procedure by (I) showing that the antiserum stained a single band of 18 kDa on western blots of rat brain particulate fractions, (2) replacing the primary antiserum with preimmune serum (not shown), and (3) demonstrating that FLAP antiserum and~S-labeled FLAP probe labeled the same neuronal elements. Both FLAP mRNA and FLAP immunostaining were dense in hippocampus (Fig. 3A, B) , where they were associated with pyramidal cells in CAl (Fig. 3C) to CA3, and with granule cells in dentate gyrus (not shown).
We also determined the cellular distribution of 5-LO mRNA. Figure 3D and E show silver grains overlying neuronal elements within the hippocampal CAl field. In agreement with the histologic localization, the number of silver grains associated with neurons was significantly higher in hippocampus than in neocortex or thalamus. We counted 16.2~1.7 grains per neuron (mean ± SEM, n = 53) in the hippocampal CAl field and 14.2 ± 1 .3 grains per neuron in the dentate gyrus.
By contrast, we measured only 6.5 ± 0.6 grains per neuron in the neocortex and 5.5 ± 0.9 grains per neuron in the thalamus (p < 0.05, ANOVA). A sense- were subjected to RT-PCR, fractionated by agarose gel electrophoresis and hybridized with selective 32P-labeled oligonucleotide probes. Two distinct probes, FLAP1 (B) and FLAP2 (C), were used to detect products of FLAP mRNA amplification (for sequences, see Experimental Procedures). Blots were exposed to x-ray films for 1 h at --80°C. Molecular sizes (in kb) of the PCR products obtained are indicated by the bars. we assessed the ability of the selective FLAP inhibitor MK-886 to affect the somatostatin augmentation of 154. We recorded intracellularly from 18 CAl pyramidal neurons with an average resting membrane potential of -69 ± 0.6 mV (mean ± SEM) and action potential amplitude of 106 ±1.3 mV. We used two drug administration protocols; in protocol I, we first superfused somatostatin (I jiM, 2-4 mm) to demonstrate an 154 increase, then washed out the peptide while superfusing MK-886 (0.25-1 jiM, 18-25 mm), and finally superfused somatostatin again (2-4 mm) in the continued presence of MK-886. In protocol 2, to ensure that the somatostatin response was not reduced by desensitization, we superfused MK-886 first and then applied somatostatin in the presence of MK-886.
Our results showed that MK-886 inhibited completely the effect of somatostatin on 'M using either protocol (Fig. 4) . Superfusion of somatostatin alone (protocol 1) increased 'M amplitude by 45 ±6 to 75 ± 16% in eight of 10 cells, with recovery to control levels after washout (15-25 mm). In the eight responding cells, somatostatin showed very little effect when reapplied in the presence of 14 ± 10% increase; Fig. 4B ). When MK-886 was superfused first (protocol 2), seven of eight cells did not show any 'M increase with subsequent somatostatin addition (1 ±7 to 8 ±5% increase overall; Fig. 4C ). To rule out nonspecific effects of MK-886 on the Mchannel, we also superfused LTC 4 in the presence of MK-886; LTC4 (6-8 pM) still increased IM (two cells; Fig. 4A ), suggesting that MK-886 prevents the somatostatin response by inhibiting biosynthesis of LTC4.
DISCUSSION
In this report we show that 5-LO and FLAP, which play a pivotal role in the cellular biosynthesis of leukotrienes in peripheral tissue, are coexpressed in discrete neuronal populations of the CNS. By combining photographic emulsion and immunohistochemical techniques, we also demonstrate that 5-LO mRNA and FLAP protein are expressed in the same neurons, as suggested by their concerted role in leukotriene biosynthesis. Our findings, together with those of Nishiyama and coworkers (1993) neurons possess the enzymatic complement necessary to produce both 5-and 12-lipoxygenase metabolites. In further support of this conclusion, formation of leukotrienes was demonstrated in a preparation of purified pinched-off synaptic terminals (synaptosomes), which contain little or no astrocyte contamination (Yates et al., 1990) . By contrast, embryonic neurons cultured in serum-free medium do not produce eicosanoids, a result that is likely explained by the culture conditions used in those experiments (Oomagari et al., 1991) .
Arachidonic acid metabolites produced via the 12-lipoxygenase pathway have been proposed to act as intracellular second messengers in invertebrate and vertebrate neurons (Piomelli et al., 1987 (Piomelli et al., , 1989 Belardetti et al., 1989; Dorman et al., 1992) . Several findings support the possibility that leukotrienes play a similar role. Here,we show that MK-886, a leukotriene biosynthesis inhibitor that acts by binding to FLAP, prevents somatostatin enhancement of the K + M-current in hippocampal pyramidal neurons. Previous studies have demonstrated that the IM-augmenting effect of somatostatin in these neurons are prevented by inhibiting PLA2 or 5-LO activities and mimicked by exogenous LTC4 (Schweitzer et al., 1990 (Schweitzer et al., , 1993 . Thus, leukotrienes may serve, in CNS neurons, a signaling function similar to that proposed for I 2-lipoxygenase metabolites in Aplysia.
Our results raise several questions. We do not know yet whether somatostatin stimulates formation of leukotrienes in hippocampal neurons, and, if so, through what mechanism. The discovery that a somatostatin receptor (SSTR4) highly expressed in hippocampus is linked to PLA2 activation and release of arachidonic acid suggests the involvement of this transmembrane signaling pathway Sakanaka et al., 1994) . Further, the mechanism of action of LTC4 in regulating M-channel function is still unknown. LTC4 may act on intracellular targets (e.g., the M-channel), as shown for I 2-lipoxygenase metabolites in Aplysia sensory neurons (Belardetti et al., 1989) . Alternatively, LTC4 may exit the cell of origin and act by binding to membrane receptors on adjacent neurons, a hypothesis supported by the occurrence of high-affinity binding sites for LTC4 in neural tissue (Schalling et al., 1986) . Interest in this question lies in the possibility that LTC4 may provide a diffusible message, of the type postulated to operate in synaptic plasticity and development, linking intracellular to extracellular signaling (Harish and Poo, 1992) . Finally, we have found other brain regions, besides hippocampus, that express relatively high levels of 5-LO and FLAP mRNAs. Further experiments are necessary to demonstrate the cellular localization of these transcripts in such regions, for instance, in the cerebellum, and to determine whether 5-LO metabolites serve signaling functions similar to that proposed here for hippocampal CAl neurons.
